Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
Status unconfirmed · Phase 2
Conditions studied: Pancreatic Cancer
In brief
The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational.
Key facts
- Study ID
- NCT03553004
- Run by
- University of Kansas Medical Center
- People needed
- 18
- Starts
- 2019-01-22
- Expected to finish
- 2025-02-01
- Last updated by the study team
- 2023-05-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Kansas Cancer Center - Clinical Research Center — Fairway, Kansas, United States
- University of Kansas Cancer Center - West — Kansas City, Kansas, United States
- University of Kansas Cancer Center - Overland Park — Overland Park, Kansas, United States
- The University of Kansas Cancer Center — Westwood, Kansas, United States
- University of Kansas Cancer Center - North — Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.